Danaher Co. (NYSE:DHR) Stock Holdings Cut by Ballentine Partners LLC

Ballentine Partners LLC lessened its position in Danaher Co. (NYSE:DHR) by 7.3% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 16,474 shares of the conglomerate’s stock after selling 1,295 shares during the period. Ballentine Partners LLC’s holdings in Danaher were worth $3,781,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Decker Retirement Planning Inc. bought a new stake in shares of Danaher in the 4th quarter worth approximately $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Danaher in the third quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new stake in shares of Danaher during the 3rd quarter valued at $40,000. FSA Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter worth $50,000. Finally, Darwin Wealth Management LLC acquired a new position in shares of Danaher in the 3rd quarter worth $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 1.4 %

DHR stock opened at $238.41 on Tuesday. Danaher Co. has a twelve month low of $222.53 and a twelve month high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The company has a market cap of $172.20 billion, a PE ratio of 45.50, a price-to-earnings-growth ratio of 4.23 and a beta of 0.83. The business’s 50-day simple moving average is $234.85 and its 200 day simple moving average is $253.51.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher’s quarterly revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the business posted $2.02 earnings per share. On average, research analysts anticipate that Danaher Co. will post 7.49 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio is 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the subject of a number of recent analyst reports. Royal Bank of Canada decreased their price target on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. UBS Group dropped their target price on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Robert W. Baird reduced their price target on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Stifel Nicolaus lifted their price objective on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Finally, Stephens reaffirmed an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research report on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.